Posts

Marrow raises $173 million to develop an siRNA approach for sickle cell disease

Marrow Therapeutics announced $173 million in combined funding: a $53 million Series A co-led by Scion Life Sciences and venBio, followed by a $120 million Series B led by OrbiMed. The funding will advance MAR-101, a preclinical candidate for sickle cell disease and beta thalassemia. It links an antibody that targets transferrin receptors to an siRNA payload intended to reduce BCL11A in bone-marrow cells, potentially restoring fetal hemoglobin production. Marrow hopes an injected treatment could avoid some burdens of current gene therapies, which can require stem-cell collection, chemotherapy conditioning and transplantation. The comparison with one-time CRISPR therapy is a development goal—not evidence that MAR-101 is as effective or durable. MAR-101 is still in IND-enabling studies; the company has not disclosed a clinical-trial start date. It has not yet shown human safety or efficacy, so the approach remains unproven. Sources: Sickle Cell Drug: Marrow Raises $173 Millio...

SELLAS reports Phase 3 survival benefit for investigational AML vaccine

Three takeaways from Isomorphic Labs’ historic $5B raise

White House withdraws Heidi Overton’s FDA nomination

Pfizer licenses Starna’s early-stage in vivo CAR-T programs

Novartis previews hematology and breast cancer data at ASH and SABCS

Siemens Healthineers and Sana Kliniken launch AI collaboration

Cradle platform use expands across argenx antibody discovery programs

Priavoid’s Alzheimer’s pill misses its Phase 2 primary efficacy target

Lilly and Stipple Bio announce oncology deal worth up to $5.9 billion

Emerging biotech hubs compete on more than cost

Flagship commits £100 million to launch AI biotech lab in London

Sofinnova closes €725M fund for late-stage life sciences companies